Valuation: Laboratorios Richmond S.A.C.I.F.

Market Cap 124B 82.45M 72.48M 67.47M 61.96M 116M 7.91B 118M 802M 313M 3.9B 310M 303M 13.49B P/E 2024
6.08x
P/E 2025 51.6x
Enterprise Value 355B 237M 208M 194M 178M 334M 22.69B 338M 2.3B 899M 11.21B 888M 869M 38.73B EV / Sales 2024
3.04x
EV / Sales 2025 3.08x
Free-Float
17.54%
Yield 2024
1.5%
Yield 2025 -
May. 10 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2026 CI
May. 07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
Mar. 06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
Nov. 05 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-08-07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-09 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-05-07 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2025 CI
25-03-07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-11-05 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-08-12 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24-05-06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
24-03-10 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
23-11-09 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
1 day-0.65%
1 week-0.65%
Current month-2.55%
1 month-4.38%
3 months-4.08%
6 months-23.88%
Current year-22.53%
1 week 1,495
Extreme 1495
1,595
1 month 1,495
Extreme 1495
1,615
Current year 1,420
Extreme 1420
2,130
1 year 945
Extreme 945
2,300
3 years 480.5
Extreme 480.5
2,300
5 years 215
Extreme 215
2,300
10 years 24.8
Extreme 24.8
2,300
Manager TitleAgeSince
President - -
General Counsel - 2025-04-28
Corporate Officer/Principal - 2025-04-28
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-0.65%-0.65%+11.27%+194.23% 83.22M
+0.13%+4.41%+47.35%+163.20% 1,067B
+0.97%+6.88%+58.02%+53.12% 635B
-0.94%+1.39%+35.02%+72.60% 458B
+1.41%+8.56%+38.93%+32.17% 347B
+1.28%+4.40%+38.42%+41.62% 295B
+1.72%+4.10%+19.31%+20.45% 262B
+1.84%-0.46%-27.78%-38.65% 216B
+0.06%+3.32%+22.73%+59.40% 203B
+0.94%-2.02%+12.32%+70.59% 161B
Average +0.68%+1.76%+25.56%+66.87% 364.36B
Weighted average by Cap. +0.60%+2.25%+36.75%+78.20%

Financials

2024 2025
Net sales 91.79B 61.26M 53.85M 50.13M 46.04M 86.45M 5.87B 87.59M 596M 233M 2.9B 230M 225M 10.03B 127B 84.57M 74.34M 69.2M 63.56M 119M 8.11B 121M 823M 321M 4B 317M 311M 13.84B
Net income 23.85B 15.91M 13.99M 13.02M 11.96M 22.46M 1.53B 22.75M 155M 60.45M 754M 59.73M 58.45M 2.6B 3.09B 2.06M 1.81M 1.69M 1.55M 2.91M 198M 2.95M 20.04M 7.83M 97.58M 7.74M 7.57M 337M
Net Debt 134B 89.19M 78.4M 72.98M 67.03M 126M 8.55B 128M 868M 339M 4.22B 335M 328M 14.6B 231B 154M 136M 126M 116M 218M 14.79B 220M 1.5B 586M 7.3B 579M 566M 25.23B
Logo Laboratorios Richmond S.A.C.I.F.
Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
Employees
620
Date Price Change Volume
26-07-27 ARS 1,530.00 -0.65% 34,559
26-07-24 ARS 1,540.00 -0.65% 13,826
26-07-23 ARS 1,550.00 +0.32% 32,355
26-07-22 ARS 1,545.00 +1.31% 855
26-07-21 ARS 1,525.00 -0.97% 1,204
  1. Stock Market
  2. Stocks
  3. RICH Stock